Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

Tommaso De Pas; Filippo De Braud; Mario Mandalà; Giuseppe Curigliano; Chiara Catania; Gianluigi Ferretti; Pietro Sozzi; Piergiorgio Solli; Aron Goldhirsch

doi:10.1016/S0169-5002(00)00176-8

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

Tommaso De Pas, Filippo De Braud, Mario Mandalà, Giuseppe Curigliano, Chiara Catania, Gianluigi Ferretti, Pietro Sozzi, Piergiorgio Solli, Aron Goldhirsch

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m² administered on day 1 and VNR 25 mg/m² administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.

Original language	English
Pages (from-to)	267-270
Number of pages	4
Journal	Lung Cancer
Volume	31
Issue number	2-3
DOIs	https://doi.org/10.1016/S0169-5002(00)00176-8
Publication status	Published - 2001

Keywords

Cisplatin
Lung cancer
Second-line chemotherapy
Vinorelbine

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S0169-5002(00)00176-8

Fingerprint Dive into the research topics of 'Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine'. Together they form a unique fingerprint.

Cite this

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. / De Pas, Tommaso ; De Braud, Filippo; Mandalà, Mario; Curigliano, Giuseppe ; Catania, Chiara; Ferretti, Gianluigi; Sozzi, Pietro; Solli, Piergiorgio; Goldhirsch, Aron.

In: Lung Cancer, Vol. 31, No. 2-3, 2001, p. 267-270.

Research output: Contribution to journal › Article › peer-review

De Pas, Tommaso ; De Braud, Filippo ; Mandalà, Mario ; Curigliano, Giuseppe ; Catania, Chiara ; Ferretti, Gianluigi ; Sozzi, Pietro ; Solli, Piergiorgio ; Goldhirsch, Aron. / Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. In: Lung Cancer. 2001 ; Vol. 31, No. 2-3. pp. 267-270.

@article{1653a7620a9641cca65944f67d51380e,

title = "Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine",

abstract = "The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m2 administered on day 1 and VNR 25 mg/m2 administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.",

keywords = "Cisplatin, Lung cancer, Second-line chemotherapy, Vinorelbine",

author = "{De Pas}, Tommaso and {De Braud}, Filippo and Mario Mandal{\`a} and Giuseppe Curigliano and Chiara Catania and Gianluigi Ferretti and Pietro Sozzi and Piergiorgio Solli and Aron Goldhirsch",

year = "2001",

doi = "10.1016/S0169-5002(00)00176-8",

language = "English",

volume = "31",

pages = "267--270",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2-3",

}

TY - JOUR

T1 - Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

AU - De Pas, Tommaso

AU - De Braud, Filippo

AU - Mandalà, Mario

AU - Curigliano, Giuseppe

AU - Catania, Chiara

AU - Ferretti, Gianluigi

AU - Sozzi, Pietro

AU - Solli, Piergiorgio

AU - Goldhirsch, Aron

PY - 2001

Y1 - 2001

N2 - The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m2 administered on day 1 and VNR 25 mg/m2 administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.

AB - The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m2 administered on day 1 and VNR 25 mg/m2 administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.

KW - Cisplatin

KW - Lung cancer

KW - Second-line chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0035144916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035144916&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(00)00176-8

DO - 10.1016/S0169-5002(00)00176-8

M3 - Article

C2 - 11165406

AN - SCOPUS:0035144916

VL - 31

SP - 267

EP - 270

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2-3

ER -